S-Space Graduate School of Convergence Science and Technology (융합과학기술대학원) Dept. of Molecular and Biopharmaceutical Sciences (분자의학 및 바이오제약학과) Theses (Master's Degree_분자의학 및 바이오제약학과)
Increased serum level of GRS antigen as a novel diagnostic biomarker for renal cell carcinoma
새로운 신세포암 진단용 생체지표로서 혈청 GRS 항원 수치의 증가
- 융합과학기술대학원 분자의학 및 바이오제약학과
- Issue Date
- 서울대학교 대학원
- Glycyl-tRNA synthetase(GRS); Renal cell carcinoma(RCC); CDH 6(K-cadherin); biomarker; Enzyme-linked immunosorbent assay(ELISA)
- 학위논문 (석사)-- 서울대학교 융합과학기술대학원 : 분자의학 및 바이오제약학과, 2013. 2. 김성훈.
- Background: There is a lack of reliable and specific markers for the diagnosis of early stage renal cell carcinoma (RCC). In renal cell carcinoma, CDH 6 expression level is increased. Furthermore, in our previous study, we founded that CDH 6 is a functional receptor for GRS (Glycyl-tRNA synthetase). This study observed level of serum GRS antigen and antibody as detection biomarkers in renal cell carcinoma.
Methods: Serum samples from patients with renal cell carcinoma were examined for serum GRS antigen and antibody level by an enzyme-linked immunosorbent assay (ELISA). The receiver operating characteristic (ROC) curves were used to determine area under the curve (AUC), sensitivity, specificity, and cut-off value for prediction of RCC.
Results: The level of serum GRS antigen was significantly higher in RCC patients than in normal human serum (NHS) (RCC 34.11 ± 9.76 ug/ml
NHS 19.22 ± 6.06 ug/ml
p < 0.0001). The AUC for GRS antigen was 0.900 (95% CI = 0.840-0.960, p < 0.0001). The sensitivity and specificity for GRS antigen detection method were 91.0 % and 75.0 %, respectively, when cut-off value of GRS antigen was 22.86 ug/ml.
Conclusions: Serum antigen level of GRS was significantly associated with RCC. GRS antigen may be a good novel biomarker or drug target for renal cell carcinoma.